Literature DB >> 22526834

Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways.

Jin Sun Yoon1, Young Woong Won, Seo Ju Kim, Suk Joong Oh, Eun Shil Kim, Byoung Kook Kim, Cheon Gyu Cho, Jung Hye Choi, Byeong Bae Park, Min Ho Lee, Young Yiul Lee.   

Abstract

Substituted 2-pyrones are important structural sub-units present in a number of natural products having broad range of biological activity. However, little is known about the anti-cancer effect of 2-pyrone derivatives including leukemia. Therefore, this present study was undertaken to investigate the effect of 2-pyrone derivatives in human acute myeloid leukemia (AML). Among 23 synthesized derivatives, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one (code name; pyrone 9) showed the most potent antileukemic activity with 5 × 10(-6) M to 5 × 10(-5) M of IC(50) in various AML cell lines as well as primary leukemic blasts from AML patients, while normal peripheral blood mononuclear cells was not affected by pyrone 9. Flow cytometric analysis indicated that pyrone 9 induced the G1 and G2 phase dual arrest of the cell cycle in HL-60 cells. To address the mechanism of the antileukemic effect of pyrone 9, we examined the effect of pyrone 9 on cell cycle-related proteins in HL-60 cell. The levels of CDK2, CDK4, CDK6, CDK1, cyclin B1 and cyclin E were decreased; in contrast, cyclin A was not altered. In addition, pyrone 9 not only increased the p27 level but also enhanced its binding to with CDK2, CDK4 and CDK6 which resulted in the reduction of CDK2-, CDK4- and CDK6-associated kinase activities. Pyrone 9 also induced the apoptosis in HL-60 cells. The apoptotic process of HL-60 cells was associated with increased Bax, decreased Bcl-2 and activation of caspase-8, -9, -3 and PARP. Antileukemic effect of pyrone 9 was associated with activation of mitogen-activated protein kinase (MAPK) pathway, as evidenced by activation of p-ERK and p38 MAPK. In addition, pyrone 9 was influenced PI3 kinase pathway. Expressions of p-Akt (ser473), p-Raf, and p-PDK were down-regulated; in contrast, those of PTEN and p-PTEN were up-regulated. Furthermore, pyrone 9 suppressed NF-κB pathway signaling. To gain insights into the antileukemic activity of pyrone 9 in vivo, BALB/c mouse leukemic model was established using intraperitoneal inoculation of syngeneic WEHI-3BD(+) mouse leukemic cells. Pyrone 9 inhibited in vitro and in vivo the growth of WEHI-3BD(+) cells, and ultimately, prolonged the survival of pyrone 9-treated mice. These findings suggest that the pyrone 9 inhibits the cell proliferation of human AML cell line, HL-60, through MAPK and PI3 kinase pathway as well as induction of cell cycle arrest. In particular, pyrone 9 prolonged the survival of pyrone 9-treated leukemic mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526834     DOI: 10.1007/s10637-012-9814-x

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  18 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  The NF-kappa B and I kappa B proteins: new discoveries and insights.

Authors:  A S Baldwin
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 3.  Regulation of transcription by proteins that control the cell cycle.

Authors:  B D Dynlacht
Journal:  Nature       Date:  1997-09-11       Impact factor: 49.962

4.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.

Authors:  H Nakshatri; P Bhat-Nakshatri; D A Martin; R J Goulet; G W Sledge
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

Review 5.  2-Pyrone natural products and mimetics: isolation, characterisation and biological activity.

Authors:  Gerard P McGlacken; Ian J S Fairlamb
Journal:  Nat Prod Rep       Date:  2005-05-05       Impact factor: 13.423

Review 6.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.

Authors:  M Hidalgo; E K Rowinsky
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

7.  The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.

Authors:  D K Biswas; S C Dai; A Cruz; B Weiser; E Graner; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

8.  IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain.

Authors:  H Sakurai; H Chiba; H Miyoshi; T Sugita; W Toriumi
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

9.  Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia.

Authors:  Jin Sun Yoon; Ju Young Kim; Hyun Ki Park; Eun Shil Kim; Kwang Sung Ahn; Sung Soo Yoon; Cheon Gyu Cho; Byoung Kook Kim; Young Yiul Lee
Journal:  Int J Oncol       Date:  2008-02       Impact factor: 5.650

10.  2-pyrones possessing antimicrobial and cytotoxic activities.

Authors:  Ian J S Fairlamb; Lester R Marrison; Julia M Dickinson; Feng-Ju Lu; Jan Peter Schmidt
Journal:  Bioorg Med Chem       Date:  2004-08-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.